Is the Race On for RNAi? A Chinese Pharma’s $450M Deal May Just Be the Start
siRNA, which operates via the RNA interference (RNAi) pathway, has the potential to silence disease-causing genes. When it is introduced into a cell, it assembles a “hit squad” -- an RNA-induced Silencing Complex (RISC) -- which looks for specific mRNA matching the siRNA's sequence. Once the target is found, the siRNA pairs with the mRNA, inducing cleavage. As the mRNA won't be translated into proteins, the action effectively puts a muffler on the gene that encodes the mRNA.
China's Hansoh Pharma believes the time is ripe to tap into gene silencing technology and has chosen to work with South Korea RNA Biotech OliX Pharmaceuticals in a deal worth over $450 million.
China's Hansoh Pharma believes the time is ripe to tap into gene silencing technology and has chosen to work with South Korea RNA Biotech OliX Pharmaceuticals in a deal worth over $450 million.
GO Prime with only $1.49 now
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13